1. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Issue 12 (December 2016) Authors: Gettinger, Scott N; Bazhenova, Lyudmila A; Langer, Corey J; Salgia, Ravi; Gold, Kathryn A; Rosell, Rafael; Shaw, Alice T; Weiss, Glen J; Tugnait, Meera; Narasimhan, Narayana I; Dorer, David J; Kerstein, David; Rivera, Victor M; Clackson, Timothy; Haluska, Frank G; Camidge, David Ross Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: 1683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Issue 1 (January 2017) Authors: Hellmann, Matthew D; Rizvi, Naiyer A; Goldman, Jonathan W; Gettinger, Scott N; Borghaei, Hossein; Brahmer, Julie R; Ready, Neal E; Gerber, David E; Chow, Laura Q; Juergens, Rosalyn A; Shepherd, Frances A; Laurie, Scott A; Geese, William J; Agrawal, Shruti; Young, Tina C; Li, Xuemei; Antonia, Scott J Journal: Lancet oncology Issue: Volume 18:Issue 1(2017:Jan.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Issue 5 (May 2020) Authors: Goldberg, Sarah B; Schalper, Kurt A; Gettinger, Scott N; Mahajan, Amit; Herbst, Roy S; Chiang, Anne C; Lilenbaum, Rogerio; Wilson, Frederick H; Omay, Sacit Bulent; Yu, James B; Jilaveanu, Lucia; Tran, Thuy; Pavlik, Kira; Rowen, Elin; Gerrish, Heather; Komlo, Annette; Gupta, Richa; Wyatt, Hailey; ... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Issue 7 (July 2016) Authors: Goldberg, Sarah B; Gettinger, Scott N; Mahajan, Amit; Chiang, Anne C; Herbst, Roy S; Sznol, Mario; Tsiouris, Apostolos John; Cohen, Justine; Vortmeyer, Alexander; Jilaveanu, Lucia; Yu, James; Hegde, Upendra; Speaker, Stephanie; Madura, Matthew; Ralabate, Amanda; Rivera, Angel; Rowen, Elin; Gerris... Journal: Lancet oncology Issue: Volume 17:Issue 7(2016:Jul.) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. (10th January 2023) Authors: Unger, Joseph M; Qian, Lu; Redman, Mary W; Tavernier, Susan S; Minasian, Lori; Sigal, Ellen V; Papadimitrakopoulou, Vassiliki A; Leblanc, Michael; Cleeland, Charles S; Dzingle, Samuel A; Summers, Thomas J; Chao, Herta; Madhusudhana, Sheshadri; Villaruz, Liza; Crawford, Jeffrey; Gray, Jhanelle E; ... Journal: Journal of the National Cancer Institute Issue: Volume 115:Number 4(2023) Page Start: 437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing. Issue 3 (March 2020) Authors: Hafez, Navid; Walther, Zenta; Eder, Joseph P; Sklar, Jeffrey L; Gettinger, Scott N; Finberg, Karin E; Goldberg, Sarah B Journal: Lancet oncology Issue: Volume 21:Issue 3(2020) Page Start: 343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗